# Nuclide record molecular-targeting-technologies (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/molecular-targeting-technologies/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "molecular-targeting-technologies" ;
  schema:name "Molecular Targeting Technologies"@en ;
  schema:alternateName "MTTI"@en, "Molecular Targeting Technologies, Inc."@en ;
  schema:description "A Pennsylvania biotech that adds a chemical 'handle' to existing radioactive cancer drugs so the drug binds briefly to albumin, the body's most abundant blood protein, letting it linger in the tumour for days on a fraction of the usual radiation dose."@en ;
  schema:url <https://nuclide.cc/companies/molecular-targeting-technologies/>, <https://www.mtarget.com> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/molecular-targeting-technologies-receives-pharma-tech-outlooks-2026-radiopharmaceutical-therapy-solution-of-the-year-award-for-evathera>, <https://www.mychesco.com/a/news/business/west-chester-biotech-targets-radiopharma-partnerships/>, <https://www.businesswire.com/news/home/20260610511667/en/MTTI-Highlights-Clinical-Experience-in-81-GEP-NETs-Patients-and-Differentiated-Profile-of-Next-Generation-PRRT-Candidate-EBTATE-Following-Presentation-at-SNMMI-2026>, <https://www.businesswire.com/news/home/20260707936626/en/Molecular-Targeting-Technologies-Presents-First-Clinical-Validation-of-the-Evans-Blue-Platform-Demonstrating-Up-to-15-Day-Tumor-Retention-Using-Approximately-12.5-of-the-Radioactivity-Required-for-Conventional-PRRT> ;
  nuclide:status "active" ;
  nuclide:tag "albumin binding", "PRRT", "EvaThera", "lutetium-177", "actinium-225" ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/targets/fap/>, <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> .